LOS ANGELES — Dodgers president of baseball operations Andrew Friedman all but confirmed Wednesday that the team would be in contact with the Tigers to gauge their asking price for reigning AL Cy Young winner Tarik Skubal.

“There just aren’t that many star-level players in the game,” Friedman said Wednesday afternoon when asked how aggressive the Dodgers would be pursuing big-name players. “Any time one is available, we’re always going to participate in those conversations. We’ve shown to be very aggressive in the past. … We’ve traded a lot of really talented young players.

“But we’re able to be in those conversations because of the incredible work by our scouts and our front office and our player development group that has our farm system in such a strong spot to be able to talk to any team basically about any player.”

All that was expected. Checking in is simply due diligence.

Friedman avoided showing his hand when asked the odds of the Dodgers acquiring a player like that at the deadline.

“I don’t know,” he said. “I’m not in the handicapping business.”

Part of the calculation, with the Tigers on a skid that could push them to sell at the deadline, will be the health of the Dodgers’ pitching staff, which is steadily improving. So, instead of trying to fill specific holes, the Dodgers have the luxury of reading the market and being “a little bit more selective and opportunistic.”

Before the Dodgers’ game against the Mariners on Wednesday, they activated closer Edwin Díaz and designated left-hander Charlie Barnes for assignment. Right-handed starter Tyler Glasnow (back spasms) threw two innings of live batting practice, and right-handed reliever Blake Treinen (right elbow inflammation) threw one simulated inning.

Over in Class A Ontario, left-hander Blake Snell (arthroscopic elbow surgery) was set to make what could be his last rehab start before being reinstated from the IL, although Friedman said the team was still talking through the next steps.

Two-way star Shohei Ohtani’s timeline back to the mound is the biggest unknown, but Friedman insisted that his lingering knee injury didn’t change the Dodgers’ evaluation of its rotation heading into the deadline.

“I don’t think it puts it in an acute need at all,” Friedman said. “A, we’re confident he’s going to come back. Again, if there was something structural, then we would be much more concerned with that. But there’s not. And the fact that it does keep improving suggests that we’re on the right path and feel very confident that he will be back.

“And then that’s also where it gets to the depth that we have and the talented arms that have stepped up with some of our injuries, that we feel like deserved an opportunity to keep going. So it just doesn’t fall into acute. That being said, we’re always open-minded to different things.”

Friedman also offered some insight on Ohtani’s right biceps injury, which he first publicly acknowledged on July 3 and that he said Tuesday night was not 100%. Ohtani hasn’t pitched in a game since that July 3 start, when the biceps issue flared in his last at-bat.

“If it weren’t for the knee, he would be pitching right now, he would be making his regular turn [in the rotation],” Friedman said. “We kept the arm going. Does he feel 100 percent in his arm? No. But neither does any pitcher in late July. But this is around the knee and making sure that we can get it to a place where there’s just no compensation. So exactly when that is, I’m not sure. But I feel confident that relatively soon, he’s going to start getting out and start ramping up for catch play and bullpens and getting him back.”

Ohtani’s timeline, however, hasn’t progressed the way the Dodgers initially expected since receiving an orthovisc injection to lubricate his knee at the beginning of the All-Star break. They’d hoped he’d return to the rotation in its first turn out of the break. Instead, he threw a bullpen in Philadelphia last week, and then his throwing program stalled.

It’s also unclear what version of Ohtani the Dodgers will get when he returns to the mound.

“There’s no question it got significantly better,” Ohtani said in Japanese of the effects of the injection. “But after talking with the doctors, I don’t think it’s realistic to expect the pain to be zero. That may end up being something that has to wait until the offseason. In the meantime, I’ll keep working through my rehab program and try to get it as close to zero (pain-free) as possible.”

While playing through the knee injury, and searching for a mechanical adjustment to take some pressure off it, Ohtani’s execution has wavered. He had a 4.38 ERA in his last four starts, compared to 0.74 in his first 10.

“I think it speaks to the knee and the delivery and just the challenge of repeating it over and over and over again,” Friedman said, “and more speaks to why we are doing this and making sure that we get it calmed down and in a good spot so he can repeat. Then I’ll bet on him to execute.”

©2026 Los Angeles Times. Visit at latimes.com. Distributed by Tribune Content Agency, LLC.